Baseline cardiovascular and cardiotoxicity risk in newly diagnosed breast cancer: insights from a nationwide turkish registry (CARPE DIEM-TR)

Clicks: 1
ID: 323370
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #94 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cardiovascular disease and cancer share common risk factors, and recent ESC cardio-oncology guidelines recommend HFA-ICOS risk stratification to define treatment-related cardiotoxicity risk. Beyond cardiotoxicity, assessment of individual baseline cardiovascular event risk is essential to guide appropriate preventive strategies. Aim This study aimed to assess baseline estimated 10-year cardiovascular disease risk, anthracycline-related cardiotoxicity risk, and variations in these risk profiles according to disease stage and pathological subgroups in women with newly diagnosed breast cancer enrolled in the CARPE DIEM-TR registry. Methods The Cardiovascular Risk Profile and Events During Treatment of Breast Cancer Patients in Türkiye (CARPE DIEM-TR) registry was initiated in 2024 to evaluate baseline cardiovascular risk factors and subsequent cardiovascular events in women with newly diagnosed BC. Patients with available data enrolled up to 15 January 2026 were included. Anthracycline (AC) cardiotoxicity risk was assessed using the HFA-ICOS risk calculator, while 10-year cardiovascular disease risk was estimated using SCORE2 and its derivatives (SCORE2-Diabetes and SCORE2-OP), as appropriate. Results The study included 333 women with BC and available SCORE2 data. Mean age was 53.2±12.8 years and mean BMI was 28.5±5.4 kg/m²; 29.4% had a smoking history. Hypertension was present in 30.9%, diabetes in 18.6%, and coronary artery disease in 2.7%. The median 10-year CVD risk was 3.3% (0–60.9%), with 54.4% classified as low risk, 6.3% moderate, 30.6% high, and 8.4% very high risk. No patients were at very high AC cardiotoxicity risk, while 58.6% were at low risk for AC cardiotoxicity. Concordance between AC cardiotoxicity risk and SCORE2 categories is shown in the Sankey plot (Figure 1). Patients with available data on cancer stage, hormone receptor status, and HER2 status were further analyzed. Patients with locally advanced disease had higher non-HDL cholesterol (144.5±42.1 vs. 160.2±44.0; p=0.021), LDL cholesterol (120.3±34.7 vs. 137.3±39.4; p=0.004), and 10-year CVD risk (2.1% vs. 4.9%; p=0.032) compared with those with early-stage disease. Body mass index was significantly higher in HER2-positive patients than in HER2-negative patients (29.8±6.2 vs. 27.8 ± 5.3; p=0.045), while all other variables were comparable. No significant differences were observed between hormone receptor–positive and –negative patients (Table 1). Conclusions HFA-ICOS cardiotoxicity risk and SCORE2 cardiovascular risk showed modest concordance, with many low cardiotoxicity–risk patients having high or very high baseline cardiovascular risk. Cardiovascular risk varied by tumor characteristics, with higher lipid levels and 10-year CVD risk in locally advanced disease and higher BMI in HER2-positive patients. These findings highlight the need for early, systematic cardiovascular risk assessment and individualized cardio-oncology strategies.Figure 1
Reference Key
openalex_W7172308102 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Y Z Sener, D M Gerede Uludag, U N Karakulak, I Ceren, F Bozduman Habip, V Kozluca, K Ohtaroglu Tokdil, F Helvacioglu, E Bozcali, E Eroglu Buyukoner
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.086
URL
https://doi.org/10.1093/eurheartjsupp/suag097.086
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.